Neville Rodie & Shaw’s Novartis NVS Stock Holding History

Neville Rodie & Shaw’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$879K	Hold	5,610	–	–	0.06%	139
2026 Q1	$857K	Sell	5,610 -800	-12%	-$123K	0.06%	135
2025 Q4	$884K	Hold	6,410	–	–	0.06%	134
2025 Q3	$822K	Hold	6,410	–	–	0.06%	143
2025 Q2	$776K	Sell	6,410 -50	-0.8%	-$5.64K	0.06%	146
2025 Q1	$720K	Hold	6,460	–	–	0.06%	152
2024 Q4	$629K	Hold	6,460	–	–	0.05%	164
2024 Q3	$743K	Hold	6,460	–	–	0.05%	148
2024 Q2	$688K	Hold	6,460	–	–	0.05%	152
2024 Q1	$624K	Hold	6,460	–	–	0.05%	163
2023 Q4	$652K	Sell	6,460 -3,452	-35%	-$333K	0.05%	155
2023 Q3	$1.01M	Sell	9,912 -20	-0.2%	-$2.03K	0.09%	123
2023 Q2	$1M	Hold	9,932	–	–	0.09%	126
2023 Q1	$914K	Hold	9,932	–	–	0.08%	136
2022 Q4	$901K	Hold	9,932	–	–	0.08%	135
2022 Q3	$755K	Hold	9,932	–	–	0.07%	139
2022 Q2	$840K	Hold	9,932	–	–	0.08%	135
2022 Q1	$871K	Hold	9,932	–	–	0.06%	145
2021 Q4	$869K	Hold	9,932	–	–	0.06%	151
2021 Q3	$812K	Hold	9,932	–	–	0.06%	147
2021 Q2	$906K	Hold	9,932	–	–	0.07%	140
2021 Q1	$849K	Hold	9,932	–	–	0.07%	138
2020 Q4	$938K	Hold	9,932	–	–	0.08%	126
2020 Q3	$864K	Hold	9,932	–	–	0.08%	123
2020 Q2	$867K	Hold	9,932	–	–	0.09%	120
2020 Q1	$819K	Hold	9,932	–	–	0.1%	120
2019 Q4	$940K	Hold	9,932	–	–	0.09%	132
2019 Q3	$863K	Hold	9,932	–	–	0.09%	128
2019 Q2	$907K	Sell	9,932 -1,152	-10%	-$97.5K	0.1%	132
2019 Q1	$955K	Hold	11,084	–	–	0.1%	125
2018 Q4	$852K	Hold	11,084	–	–	0.1%	127
2018 Q3	$856K	Hold	11,084	–	–	0.08%	137
2018 Q2	$750K	Hold	11,084	–	–	0.08%	143
2018 Q1	$803K	Hold	11,084	–	–	0.09%	141
2017 Q4	$834K	Hold	11,084	–	–	0.09%	141
2017 Q3	$853K	Hold	11,084	–	–	0.1%	136
2017 Q2	$829K	Hold	11,084	–	–	0.09%	133
2017 Q1	$738K	Hold	11,084	–	–	0.08%	147
2016 Q4	$723K	Hold	11,084	–	–	0.09%	143
2016 Q3	$784K	Hold	11,084	–	–	0.09%	143
2016 Q2	$819K	Hold	11,084	–	–	0.1%	144
2016 Q1	$719K	Hold	11,084	–	–	0.09%	142
2015 Q4	$855K	Hold	11,084	–	–	0.1%	136
2015 Q3	$913K	Sell	11,084 -112	-1%	-$9.97K	0.11%	134
2015 Q2	$987K	Hold	11,196	–	–	0.11%	134
2015 Q1	$989K	Sell	11,196 -111	-1%	-$9.85K	0.1%	142
2014 Q4	$939K	Sell	11,307 -162	-1%	-$13.4K	0.1%	145
2014 Q3	$967K	Buy	+11,469	New	+$928K	0.1%	142

Other funds holding NVS

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

GGI

Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

Neville Rodie & Shaw's NVS Position: Q2 2026 in Review

Neville Rodie & Shaw held its Novartis (NVS) position steady in Q2 2026 at 5,610 shares worth $879K. The position accounts for 0.06% of the portfolio, ranked #139.

Neville Rodie & Shaw first reported a position in NVS in Q3 2014 and has held it in 48 quarters since. The position peaked at $1.01M in Q3 2023. 623 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Neville Rodie & Shaw held 5,610 shares of Novartis worth $879K as of Q2 2026.
Neville Rodie & Shaw left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.06% of Neville Rodie & Shaw's portfolio in Q2 2026, its #139 holding.
Neville Rodie & Shaw first reported a position in Novartis in Q3 2014 and has held it in 48 quarters since.
Neville Rodie & Shaw's Novartis position peaked at $1.01M in Q3 2023.
623 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Neville Rodie & Shaw's 13F filing for Q2 2026, filed 6 Jul 2026.